Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients
- 1 January 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (1), 102-109
- https://doi.org/10.1200/jco.2006.08.1075
Abstract
Purpose To report the results of a planned safety analysis from a phase III trial comparing capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil/leucovorin (FU/LV) as adjuvant therapy for stage III colon cancer. Patients and Methods Patients with stage III colon carcinoma were randomly assigned to receive either XELOX (intravenous oxaliplatin plus oral capecitabine; 3-week cycle for eight cycles) or standard intravenous bolus FU/LV administered as the Mayo Clinic (Mayo; Rochester, MN) or Roswell Park (RP; Buffalo, NY) regimen for a similar length of time. A total of 1,886 patients were randomly assigned. Results The safety population comprised 1,864 patients, of whom 938 received XELOX and 926 received FU/LV. Most treatment-related adverse events (AEs) occurred at similar rates in both treatment arms. However, patients receiving XELOX experienced less all-grade diarrhea, alopecia, and more neurosensory toxicity, vomiting, and hand-foot syndrome than those patients receiving FU/LV. Compared with Mayo, XELOX showed fewer grade 3/4 hematologic AE and more grade 3/4 gastrointestinal AE. Compared with RP, XELOX showed less grade 3/4 gastrointestinal AE and more grade 3/4 hematologic AE. As expected grade 3/4 neurosensory toxicity and grade 3 hand-foot syndrome were higher with XELOX. Treatment-related mortality within 28 days from the last study dose was 0.6% in the XELOX group and 0.6% in the FU/LV group. Conclusion XELOX has a manageable tolerability profile in the adjuvant setting. Efficacy data will be available within the next 24 months.Keywords
This publication has 15 references indexed in Scilit:
- Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialBritish Journal of Cancer, 2006
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerNew England Journal of Medicine, 2005
- Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)Journal of Clinical Oncology, 2005
- In Reply:Journal of Clinical Oncology, 2005
- Analysis of over 2,400 modern phase I cancer trials: Composition, outcomes, and use of surrogate endpointsJournal of Clinical Oncology, 2004
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsBritish Journal of Cancer, 2004
- Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trialAnnals of Oncology, 2003
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002
- Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinomaEuropean Journal Of Cancer, 2001